MX2023006083A - Npp1 para usarse en el tratamiento de calcificacion de tejidos. - Google Patents

Npp1 para usarse en el tratamiento de calcificacion de tejidos.

Info

Publication number
MX2023006083A
MX2023006083A MX2023006083A MX2023006083A MX2023006083A MX 2023006083 A MX2023006083 A MX 2023006083A MX 2023006083 A MX2023006083 A MX 2023006083A MX 2023006083 A MX2023006083 A MX 2023006083A MX 2023006083 A MX2023006083 A MX 2023006083A
Authority
MX
Mexico
Prior art keywords
calcification
npp1
treating tissue
provides
methods
Prior art date
Application number
MX2023006083A
Other languages
English (en)
Inventor
Anthony Quinn
Nelson Hsia
Tayeba Khan
Gregory Grabowsky
Zhiliang Cheng
W Charles O'neill
Kym Lynette ASKEW
Original Assignee
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharma Inc filed Critical Alexion Pharma Inc
Publication of MX2023006083A publication Critical patent/MX2023006083A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04001—Phosphodiesterase I (3.1.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
    • C12Y306/01009—Nucleotide diphosphatase (3.6.1.9), i.e. nucleotide-pyrophosphatase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La presente invención proporciona composiciones para usarse en el tratamiento de la deficiencia de NPP1 o una enfermedad asociada con NPP1 tal como la calcificación arterial idiopática infantil (IIAC), pseudoxantoma elástico, calcificación vascular en enfermedad renal crónica (VCCKD), resistencia a la insulina, raquitismo hipofosfatémico, isquemia del miocardio, calcificación de articulaciones, estrías angioides, y osificación del ligamento longitudinal posterior de la espina.
MX2023006083A 2014-12-19 2017-06-15 Npp1 para usarse en el tratamiento de calcificacion de tejidos. MX2023006083A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462094943P 2014-12-19 2014-12-19
US201562249781P 2015-11-02 2015-11-02

Publications (1)

Publication Number Publication Date
MX2023006083A true MX2023006083A (es) 2023-06-19

Family

ID=56127864

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2017007946A MX2017007946A (es) 2014-12-19 2015-12-18 Metodos para tratar la calcificacion de tejidos.
MX2023006083A MX2023006083A (es) 2014-12-19 2017-06-15 Npp1 para usarse en el tratamiento de calcificacion de tejidos.
MX2022011281A MX2022011281A (es) 2014-12-19 2017-06-15 Npp1 para usarse en el tratamiento de calcificacion de tejidos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017007946A MX2017007946A (es) 2014-12-19 2015-12-18 Metodos para tratar la calcificacion de tejidos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022011281A MX2022011281A (es) 2014-12-19 2017-06-15 Npp1 para usarse en el tratamiento de calcificacion de tejidos.

Country Status (15)

Country Link
US (2) USRE49529E1 (es)
EP (3) EP3234116B1 (es)
JP (3) JP2018500315A (es)
KR (1) KR20170095367A (es)
CN (1) CN107109381A (es)
AU (1) AU2015364411A1 (es)
BR (1) BR112017012928A2 (es)
CA (1) CA2971414A1 (es)
CO (1) CO2017006032A2 (es)
ES (2) ES2981606T3 (es)
HK (1) HK1245662A1 (es)
MX (3) MX2017007946A (es)
PL (1) PL3967755T3 (es)
RU (1) RU2770698C2 (es)
WO (1) WO2016100803A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2956163A4 (en) * 2013-02-13 2017-03-22 Yale University Compositions and methods for treating pathological calcification and ossification
EP3234116B1 (en) 2014-12-19 2021-09-08 Alexion Pharmaceuticals, Inc. Methods of treating tissue calcification
MX2017014805A (es) 2015-05-19 2018-02-15 Univ Yale Composiciones para el tratamiento de condiciones patologicas de calcificacion y sus metodos de uso.
EP3827835A1 (en) 2016-06-16 2021-06-02 Inozyme Pharma, Inc. Methods of treating myointimal proliferation
JP2019532915A (ja) 2016-08-05 2019-11-14 イエール ユニバーシティ 小児鎌状赤血球貧血患者における脳卒中予防のための組成物および方法
CA3096821A1 (en) * 2017-09-27 2019-04-04 Inozyme Pharma, Inc. Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (npp1)
AU2019267545A1 (en) * 2018-05-08 2020-11-26 Yale University Compositions and methods for reducing progression of nephrolithiasis
AU2019327572A1 (en) * 2018-08-31 2021-03-18 Yale University ENPP1 polypeptides and methods of using same
CA3126839A1 (en) * 2019-01-18 2020-07-23 Inozyme Pharma, Inc. Treatment of diseases involving deficiency of enpp1 or enpp3
CA3181983A1 (en) * 2020-06-09 2021-12-16 Zhiliang Cheng Soluble enpp1 or enpp3 proteins and uses thereof
CA3198957A1 (en) * 2020-11-19 2022-05-27 Pedro Huertas Treatment of enpp1 deficiency and abcc6 deficiency

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US6267964B1 (en) 1989-08-01 2001-07-31 Affibody Technology Sweden Ab Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
DE69833779T2 (de) 1997-11-07 2006-11-30 Trillium Therapeutics Inc., Toronto Verfahren und zusammensetzungen zur immunomodulation
US6272859B1 (en) 1998-10-02 2001-08-14 Caterpillar Inc. Device for controlling a variable geometry turbocharger
CA2390691C (en) 1999-12-24 2016-05-10 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
DE60140349D1 (de) 2000-02-23 2009-12-17 Pxe Internat Inc Methoden und zusammensetzungen zur diagnose und behandlung von pseudoxanthoma elasticum und ähnlichen zuständen
US7211395B2 (en) 2001-03-09 2007-05-01 Dyax Corp. Serum albumin binding moieties
US7858297B2 (en) 2001-12-18 2010-12-28 Centre National De La Recherche Scientifique Cnrs Chemokine-binding protein and methods of use
AU2003213246A1 (en) 2002-02-21 2003-09-09 University Of Virginia Patent Foundation Bone targeting peptides
EP1572936A2 (en) 2002-03-05 2005-09-14 Eli Lilly And Company Heterologous g-csf fusion proteins
JP2006512050A (ja) 2002-06-21 2006-04-13 ダイアックス、コープ 血清タンパク質結合標的特異的リガンドとその同定方法
EP1729795B1 (en) 2004-02-09 2016-02-03 Human Genome Sciences, Inc. Albumin fusion proteins
US20050287284A1 (en) 2004-06-28 2005-12-29 Shukla Triveni P Processed meats comprising dietary fiber gel
US20090142347A1 (en) * 2004-09-29 2009-06-04 The Burnham Institute For Medical Research Tissue-Nonspecific Alkaline Phosphatase (TNAP): a Therapeutic Target for Arterial Calcification
WO2008028977A2 (en) 2006-09-08 2008-03-13 Ablynx N.V. Serum albumin binding proteins with long half-lives
US8846603B2 (en) 2010-03-12 2014-09-30 Synageva Biopharma Corp. NPP1 fusion proteins
RU2601154C2 (ru) 2011-03-11 2016-10-27 Синаджива Байофарма Корп Гибридные белки npp1
EP2956163A4 (en) 2013-02-13 2017-03-22 Yale University Compositions and methods for treating pathological calcification and ossification
EP3234116B1 (en) * 2014-12-19 2021-09-08 Alexion Pharmaceuticals, Inc. Methods of treating tissue calcification
MX2017014805A (es) * 2015-05-19 2018-02-15 Univ Yale Composiciones para el tratamiento de condiciones patologicas de calcificacion y sus metodos de uso.
EP4079322A1 (en) 2015-11-20 2022-10-26 Yale University Compositions for treating ectopic calcification disorders, and methods using same

Also Published As

Publication number Publication date
BR112017012928A2 (pt) 2018-05-15
EP3967755A1 (en) 2022-03-16
JP2024010052A (ja) 2024-01-23
RU2017119466A (ru) 2019-01-21
JP2018500315A (ja) 2018-01-11
HK1245662A1 (zh) 2018-08-31
MX2017007946A (es) 2017-09-15
US20180318400A1 (en) 2018-11-08
KR20170095367A (ko) 2017-08-22
PL3967755T3 (pl) 2024-08-19
WO2016100803A2 (en) 2016-06-23
MX2022011281A (es) 2022-10-18
JP2022003048A (ja) 2022-01-11
WO2016100803A3 (en) 2016-08-04
CO2017006032A2 (es) 2017-10-20
ES2899895T3 (es) 2022-03-15
RU2770698C2 (ru) 2022-04-21
CN107109381A (zh) 2017-08-29
USRE49529E1 (en) 2023-05-16
RU2017119466A3 (es) 2019-12-20
EP4438118A2 (en) 2024-10-02
CA2971414A1 (en) 2016-06-23
EP3234116B1 (en) 2021-09-08
US10493135B2 (en) 2019-12-03
EP3967755B1 (en) 2024-03-27
EP3234116A4 (en) 2018-08-01
EP3234116A2 (en) 2017-10-25
ES2981606T3 (es) 2024-10-09
AU2015364411A1 (en) 2017-06-08

Similar Documents

Publication Publication Date Title
MX2022011281A (es) Npp1 para usarse en el tratamiento de calcificacion de tejidos.
PH12018500714A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
EA201990293A1 (ru) Мультиспецифичные антитела против cd40 и cd137
MX2019008085A (es) Antagonistas de activina-actrii y usos para tratar transtornos oseos y otros.
MX2017013562A (es) Reguladores de microbioma y usos relacionados de los mismos.
MX2021000848A (es) Compuestos y sus usos para modular la hemoglobina.
EA201791093A1 (ru) Антитела к cd47, способы и применение
PH12014502437A1 (en) Anti-egfr antibodies and uses threof
MY175708A (en) Dna antibody constructs and method of using same
BR122020024446B8 (pt) Compostos para modulação da expressão do receptor do hormônio de crescimento
MX2015011509A (es) Compuestos y usos de estos para la modulacion de la hemoglobina.
MX350861B (es) Anticuerpos frente al receptor del factor de crecimiento epidérmico (egfr) y usos de éstos.
MX2015011445A (es) Compuestos y usos de estos para la modulacion de la hemoglobina.
MX2017003247A (es) Proteina de union a antigenos, bi-especificos del receptor anti-cgrp/receptor pac1 y usos de las mismas.
MX2021003740A (es) El control efectivo y eficaz del fosfato serico para una osificacion optima.
EA202090946A3 (ru) Композиции, обеспечивающие пропускание экзонов, для лечения мышечной дистрофии
MX2018000352A (es) 4-azaindoles sustituidos y su uso como moduladores del receptor glun2b.
PH12019501405A1 (en) Anti-neuropilin antigen-binding proteins and methods of use thereof
MX2023009421A (es) Construcciones de anticuerpos de adn y metodo para utilizarlas.
MX2016014559A (es) Compuestos para el tratamiento de cancer.
MX2016010030A (es) Proteina quimerica compuesta del dominio antagonista de factor de crecimiento nervioso secretado (ngf) y un dominio antagonista de factor alfa de necrosis tumoral (tnfa).
EA201500670A1 (ru) Egfr-направленная терапия неврологических нарушений и боли
MX2018002304A (es) Composiciones minerales para la estimulacion del metabolismo de los hidratos de carbono.
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
EP4328245A3 (en) Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations